Insulet Announces Concurrent Public Offerings of Notes and Common Stock Issued in Previously Announced Neighborhood Diabetes Acquisition

Insulet Corporation PODD today announced its intention to offer, subject to market and other conditions, $110 million principal amount of convertible senior notes due 2016 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission today. Insulet also intends to grant the underwriters an option to purchase up to an additional $16.5 million principal amount of notes to cover over-allotments, if any. Insulet intends to use the net proceeds from the notes offering for general corporate purposes, including the possible repurchase of existing debt securities, which mature in June 2013. Insulet will not receive any of the proceeds from the common stock offering.